Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Status Completed

Clinical Trial Summary

This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy.

Clinical Trial Description

This is a multicentre, randomized, double-blind, placebo-controlled trial that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy. Patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio after the ICF was received. Patients in one arm will be given 15 ml edaravone and dexborneol concentrated solution for injection (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) twice a day for 10-14 days, and those in the other arm will be given an equivalent placebo drug. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2 and the safety outcome is the proportion of severe adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05249920
Study type	Interventional
Source	Beijing Tiantan Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	March 18, 2022
Completion date	May 19, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06113848` - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy	Phase 3
Completed	`NCT04069546` - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency	N/A
Active, not recruiting	`NCT05700097` - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy	Phase 2
Recruiting	`NCT06058130` - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis	N/A
Recruiting	`NCT04415164` - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke	Phase 4
Recruiting	`NCT05363397` - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke	Phase 2
Completed	`NCT05429658` - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System	N/A
Recruiting	`NCT05390580` - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct	N/A
Enrolling by invitation	`NCT05515393` - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke	Phase 2
Active, not recruiting	`NCT05070260` - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo	Phase 2/Phase 3
Terminated	`NCT05547412` - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed	`NCT03366818` - New Stent Retriever, VERSI System for AIS	N/A
Not yet recruiting	`NCT06040476` - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)	Phase 2
Not yet recruiting	`NCT06437431` - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy	Phase 2/Phase 3
Not yet recruiting	`NCT05293080` - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE	Phase 3
Completed	`NCT02223273` - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)	N/A
Completed	`NCT02586233` - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke	Phase 1/Phase 2
Not yet recruiting	`NCT01594190` - Physical Activity Immediately After Acute Cerebral Ischemia	N/A
Terminated	`NCT01694381` - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor	Early Phase 1
Completed	`NCT01120301` - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)	Phase 3